Human Oncology & Pathogenesis Program
The Yu Chen Lab
The major goal of my laboratory is to understand how critical transcription factors mediate prostate cancer oncogenesis. Prostate cancers uniquely harbor very few mutations in well-known driver oncogenes (e.g., RAS, BRAF, etc.). Instead, they are characterized by aberrations in transcription factors, including the androgen receptor (AR) and ETS family transcription factors. These oncogenic transcription factors regulate a transcriptional program that determines cellular lineage, specifies the responses to external stimuli, and contributes to the oncogenic cellular context in prostate cancer. Our long-term goal is to generate an integrative understanding of how transcription factors normally guide the prostate lineage determination and how their deregulation leads to cancer. In addition, using biochemistry and genetic screens, we are pursuing ways to target the activity of these transcription factors that can lead to drug discovery.
Sumiyoshi T, Chi KN, Wyatt AW. Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):310-322.
Galbo PM Jr, Zang X, Zheng D. Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance. Clin Cancer Res. 2021 May 1;27(9):2636-2647.
Hitchman TD, Bayshtok G, Ceraudo E, Moore AR, Lee C, Jia R, Wang N, Pachai MR, Shoushtari AN, Francis JH, Guan Y, Chen J, Chang MT, Taylor BS, Sakmar TP, Huber T, Chi P, Chen Y. Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. Clin Cancer Res. 2021 Mar 1;27(5):1476-1490.
Berchuck JE, Viscuse PV, Beltran H, Aparicio A. Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis. 2021 Feb 10;.
Dhimolea E, de Matos Simoes R, Kansara D, Al’Khafaji A, Bouyssou J, Weng X, Sharma S, Raja J, Awate P, Shirasaki R, Tang H, Glassner BJ, Liu Z, Gao D, Bryan J, Bender S, Roth J, Scheffer M, Jeselsohn R, Gray NS, Georgakoudi I, Vazquez F, Tsherniak A, Chen Y, Welm A, Duy C, Melnick A, Bartholdy B, Brown M, Culhane AC, Mitsiades CS. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell. 2021 Feb 8;39(2):240-256.e11.
Yu Chen, MD, PhD
- Physician-scientist Yu Chen studies the role of transcription factors that are critical for prostate cancer development.
- MD, Weill Cornell Medical College
- PhD, The Rockefeller University
- View physician profile
- Physician profile
- Louis V. Gerstner Young Investigator Award, Memorial Sloan Kettering Cancer Center (2011)
- Young Investigator Award, Prostate Cancer Foundation (2011)
- Physician Research Training Award, Department of Defense Prostate Cancer Research Program (2010)
- Advanced Fellowship Award, Charles H. Revson Foundation (2009)
- K08 Clinical Scientist Development Award, National Institutes of Health (2009)
- Clinical Scholars Award, Memorial Sloan Kettering Cancer Center (2008)
- Young Investigator Award, American Society of Clinical Oncology (2007)
- Clinical Cancer Research Award, American Association for Cancer Research/Bristol-Myers Squibb (2007)
To learn more about available postdoctoral opportunities, please visit our Career Center
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Yu Chen discloses the following relationships and financial interests:
Intellectual Property Rights; Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.